Chemotherapy-Induced Neutropenic Enterocolitis in Acute Myeloid Leukaemia Patient: A Case Report
Abstract:
This
case report details a 53-year-old woman with newly diagnosed acute myelogenous leukaemia
(AML) who developed neutropenic enterocolitis (typhlitis) following induction
chemotherapy. Initially presenting with mild respiratory symptoms and blood
abnormalities, her condition worsened after chemotherapy, leading to severe
gastrointestinal issues and pancytopenia. Diagnostic imaging and blood cultures
confirmed neutropenic enterocolitis caused by Escherichia coli. The patient was
successfully treated with broad-spectrum antibiotics, G-CSF, blood
transfusions, and supportive care, resulting in a full recovery. This case
highlights the importance of early diagnosis and prompt treatment of
neutropenic enterocolitis in AML patients undergoing chemotherapy to improve
outcomes and reduce mortality.
References:
[1].
Gorschlüter, M., Mey,
U., Strehl, J., Ziske, C., Schepke, M., Schmidt‐Wolf, I. G., Sauerbruch, T.,
and Glasmacher, A., 2005, Neutropenic enterocolitis in adults: systematic
analysis of evidence quality. European journal of Haematology, 75(1),
pp.1-13. https://doi.org/10.1111/j.1600-0609.2005.00442.x
[2].
Rodrigues, F. G., Dasilva, G., and
Wexner, S. D., 2017, Neutropenic enterocolitis. World journal of Gastroenterology, 23(1), p.42. doi:
10.3748/wjg.v23.i1.42.
[3].
Kondoh, D., Kamikawa,
A., Sasaki, M., and Kitamura, N., 2017, Localization of α1-2 fucose glycan in
the mouse olfactory pathway. Cells Tissues Organs, 203(1),
pp.20-28. doi:10.1159/000447009.
[4].
Döhner, H., Weisdorf, D.
J., and Bloomfield, C. D., 2015, Acute myeloid leukaemia. New England Journal
of Medicine, 373(12), pp.1136-1152. doi:10.1056/NEJMra1406184.
[5].
Langebrake, C.,
Creutzig, U., Dworzak, M., Hrusak, O., Mejstrikova, E., Griesinger, F.,
Zimmermann, M., and Reinhardt, D., 2006, Residual disease monitoring in
childhood acute myeloid leukaemia by multiparameter flow cytometry: the
MRD-AML-BFM Study Group. Journal of Clinical Oncology, 24(22),
pp.3686-3692. https://doi.org/10.1200/JCO.2005.05.4312.
[6].
Becker, E. C., Tafader,
A., and Bath, R. K., 2022, Neutropenic Enterocolitis in a Patient With Acute
Myeloid Leukemia. Cureus, 14(7). doi: 10.7759/cureus.26712.
[7].
Borgstedt-Bendixen, S. E.,
Abrahamsson, J., Ha, S. Y., Koskenvuo, M., Lausen, B., Palle, J., Zeller, B.,
Hasle, H., and Løhmann, D. J., 2022, Abdominal complications during treatment
for pediatric acute myeloid leukaemia. Journal of pediatric
hematology/oncology, 44(5), pp.220-229. DOI: 10.1097/MPH.0000000000002281.
[8].
Portugal, R., and Nucci,
M., 2017, Typhlitis (neutropenic enterocolitis) in patients with acute
leukemia: a review. Expert review of hematology, 10(2),
pp.169-174. https://doi.org/10.1080/17474086.2017.1280389.
[9].
Abu-Sbeih, H., Ali, F. S.,
Chen, E., Mallepally, N., Luo, W., Lu, Y., Foo, W. C., Qiao, W., Okhuysen, P. C.,
Adachi, J. A., and Hachem, R. Y., 2020, Neutropenic enterocolitis: clinical
features and outcomes. Diseases of the Colon & Rectum, 63(3),
pp.381-388. DOI: 10.1097/DCR.0000000000001548.
[10].
Bertozzi, G., Maiese,
A., Passaro, G., Tosoni, A., Mirijello, A., Simone, S. D., Baldari, B.,
Cipolloni, L., and La Russa, R., 2021, Neutropenic enterocolitis and sepsis:
towards the definition of a pathologic profile. Medicina, 57(6),
p.638. https://doi.org/10.3390/medicina57060638.
[11]. Cartoni, C., Dragoni, F., Micozzi,
A., Pescarmona, E., Mecarocci, S., Chirletti, P., Petti, M. C., Meloni, G., and
Mandelli, F., 2001, Neutropenic enterocolitis in patients with acute leukemia:
prognostic significance of bowel wall thickening detected by
ultrasonography. Journal of Clinical Oncology, 19(3),
pp.756-761. https://doi.org/10.1200/JCO.2001.19.3.756.
[12]. Davila, M. L., 2007, Neutropenic
enterocolitis: current issues in diagnosis and management. Current
infectious disease reports, 9(2), pp.116-120. https://doi.org/10.1007/s11908-007-0006-3.
[13].
Cross, S. J., Patel, J. R.,
and Wolf, J., 2022, Diagnosis and management of typhlitis and neutropenic
enterocolitis in children with cancer. The Pediatric Infectious Disease
Journal, 41(8), pp.e326-e328. DOI: 10.1097/INF.0000000000003556.
[14].
Saritha, P.,
Arunprakash, S., Srinivasan, P., Selvankumar, T., Aldawood, S., Kim, W., &
Song, K. S., 2024, Synthesis of Luminescent Copper Nanoparticles Using
Couroupita guianensis Flower Extract: Evaluation of Antibacterial and
Anticancer Activities. Luminescence, 39(10), e4913.
[15].
Abareethan, M.,
Sathiyapriya, R., Pavithra, M. E., Parvathy, S., Thirumalaisamy, R.,
Selvankumar, T., & Almoallim, H. S., 2024, Biogenic silver nanoparticles
from Solanum trilobatum leaf extract and assessing their antioxidant and
antimicrobial potential. Chemical Physics Impact, 9, 100771.
[16].
Jaganathan, R.,
Kumaradhas, P., 2024, Structural insights into Furin enzyme inhibition to block
SARS-CoV-2 spike protein cleavage: an in-silico approach. 3 Biotech,
14(9), 213.
[17]. Muthuvel, R.,
Jagannathan, S., Pariyapurath, N. K., Pachamuthu, R. G., Mathanmohun, M., &
Sagadevan, S., 2024, Harnessing Nutritional Powerhouse: Millets and Probiotics
in Anticancer Therapy. Current Pharmacology Reports, 1-8.
[18]. Pariyapurath, N.
K., Jagannathan, S., Mathanmohun, M., Pillai, S. B., Dhandapani, K.,
Pachamuthu, R. G., & Namassivayam, H., 2024,. Targeted Immunization
Strategies and Designing Vaccine against Indian Nipah Virus Strain (NiV B) and
Malaysian Variant (NiV M). International Journal of Pharmaceutical
Investigation, 14(4).
